Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
While access remains uneven across commercial plans and Medicare coverage for obesity medicines is still limited, CVS decision signals continued normalization of GLP-1 therapies within mainstream pharmacy benefit design and intensifies competition between Lilly and Novo Nordisk for long-term market leadership in obesity careTop of FormBottom of Form Sources CVS brings back coverage for Lilly's obesity drug Zepbound Reuters May 28, 2026 Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge Reuters May 1, 2025
Bacteriostatic water (0.9% benzyl alcohol) is the standard diluent for research peptides, extending reconstituted solution stability to 28 days when refrigerated
As stated in storage guidance, keeping the temperature in check helps the medicine stay stable and effective
H.WengM
US$ 20.13
US$ 22.87
US$ 26.77
US$ 23.12
US$ 26.44
US$ 25.81
US$ 27.92
US$ 29.13
